Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayvon Modjarrad

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
NPJ Vaccines|January 28, 2022
Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosetsIn-Jeong Kim, Paula A Lanthier, Madeline J Clark, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Nature Communications|August 19, 2020
Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-timeKayla G Barnes, Anna E Lachenauer, Adam Nitido, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
BMC Infectious Diseases|October 7, 2024
Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional studyAbdulwasiu B Tiamiyu, Olutunde A Adegbite, Olivia Freides, et al.
Vaccines|May 28, 2022
A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) ModelSara C Johnston, Keersten M Ricks, Ines Lakhal-Naouar, et al.
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Nature Communications|February 3, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivityWei-Hung Chen, Agnes Hajduczki, Elizabeth J Martinez, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
NPJ Vaccines|January 28, 2022
Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosetsIn-Jeong Kim, Paula A Lanthier, Madeline J Clark, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Nature Communications|August 19, 2020
Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-timeKayla G Barnes, Anna E Lachenauer, Adam Nitido, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
BMC Infectious Diseases|October 7, 2024
Seroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional studyAbdulwasiu B Tiamiyu, Olutunde A Adegbite, Olivia Freides, et al.
Vaccines|May 28, 2022
A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) ModelSara C Johnston, Keersten M Ricks, Ines Lakhal-Naouar, et al.
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Nature Communications|February 3, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivityWei-Hung Chen, Agnes Hajduczki, Elizabeth J Martinez, et al.
Pageof 14